Evidence map›Paper›PMID 34625812›Full record

ArticleThe Journal of nutrition2022

A Novel Ferritin-Core Analog Is a Safe and Effective Alternative to Oral Ferrous Iron for Treating Iron Deficiency during Pregnancy in Mice.

Sheridan L Helman, Sarah J Wilkins, Daniel R McKeating, Anthony V Perkins, James S M Cuffe, Gunter Hartel, Nuno Faria, Jonathan J Powell, Gregory J Anderson, David M Frazer

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in The Journal of nutrition, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Observational
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Sheridan L HelmanMolecular Nutrition Laboratory, QIMR Berghofer Medical Research Institute, Herston, Australia.ORCID 0000-0002-2185-2988
Sarah J WilkinsIron Metabolism Laboratory, QIMR Berghofer Medical Research Institute, Herston, Australia.
Daniel R McKeatingSchool of Pharmacy and Medical Sciences, Griffith University, Southport, Australia.
Anthony V PerkinsSchool of Pharmacy and Medical Sciences, Griffith University, Southport, Australia.
James S M CuffeSchool of Biomedical Sciences, The University of Queensland, St Lucia, Australia.
Gunter HartelStatistics Unit, QIMR Berghofer Medical Research Institute, Herston, Australia.
Nuno FariaBiomineral Research Group, Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom.
Jonathan J PowellBiomineral Research Group, Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom.
Gregory J AndersonIron Metabolism Laboratory, QIMR Berghofer Medical Research Institute, Herston, Australia.
David M FrazerMolecular Nutrition Laboratory, QIMR Berghofer Medical Research Institute, Herston, Australia.ORCID 0000-0003-4098-1379
The University of Queensland · AUGriffith University · AUQIMR Berghofer Medical Research Institute · AUUniversity of Cambridge · GBQueensland University of Technology · AU

Funding

Medical Research Council MR/R005699/1
6 · The paper itself

Abstract

backgroundMany women enter pregnancy with iron stores that are insufficient to maintain maternal iron balance and support fetal development and consequently, often require iron supplements. However, the side effects associated with many currently available iron supplements can limit compliance.

objectiveThis study aimed to test the safety and efficacy of a novel nanoparticulate iron supplement, a dietary ferritin analog termed iron hydroxide adipate tartrate (IHAT), in pregnant mice.

methodsFemale C57BL/6 mice were maintained on either an iron-deficient or a control diet for 2 wk prior to timed mating to develop iron-deficient or iron-sufficient pregnancy models, respectively. Mice from each model were then gavaged daily with 10 mg iron/kg body weight as either IHAT or ferrous sulfate, or with water only, beginning on embryonic day (E) 4.5. Mice were killed on E18.5 and maternal iron and hematological parameters were measured. The expression of genes encoding iron transporters and oxidative stress markers in the duodenum and placenta were determined, along with hepatic expression of the gene encoding the iron regulatory hormone hepcidin and fetal iron.

resultsOral IHAT and ferrous sulfate were equally effective at increasing maternal hemoglobin (20.2% and 16.9%, respectively) and hepatic iron (30.2% and 29.3%, respectively), as well as total fetal iron (99.7% and 83.8%, respectively), in iron-deficient pregnant mice compared with those gavaged with water only, with no change in oxidative stress markers seen with either treatment. However, there was a significant increase in the placental expression of the oxidative stress marker heme oxygenase 1 in iron-replete pregnant mice treated with ferrous sulfate when compared with iron-replete pregnant mice gavaged with IHAT (96.9%, P <0.05).

conclusionsIHAT has proved a safe and effective alternative to oral ferrous sulfate in mice, and it has potential for treating iron deficiency in human pregnancy.

Indexed as

Anemia, Iron-DeficiencyIron DeficienciesAnimalsFemaleFerritinsFerrous CompoundsHemoglobinsHumansIronMiceMice, Inbred C57BLPlacentaPregnancyWaterFerritinsFerrous CompoundsHemoglobinsIronWaterfetal nutritioniron deficiencyiron supplementnanoparticulate ironoxidative stress

Identifiers

PMID34625812
OpenAlexW3204274890

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.